Brought to you by 
ABK Biomedical raises $30mm in Series B round
10 Apr 2019
Executive Summary
ABK Biomedical Inc. (developing microspheres for embolization procedures) raised $30mm through its Series B round co-led by F-Prime and Varian Medical Systems. The company will put the proceeds towards continued development of the Easi-Vue microspheres for treatment of hypervascular tumors and the Eye90 radio-opaque yttrium-90 microspheres for transarterial radiation of liver tumors. First-in-human use of Eye90 is expected in 2020, while the Easi-Vue could be in human studies later this year.
Deal Industry
- Biotechnology
- Medical Devices
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ABK Biomedical raises $30mm in Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice